Dealmakers share how they see AI changing the landscape next year. Kenny Walker-Durrant, partner in Technology and Life Sciences at Goodwin, says, "AI will continue to disrupt drug discovery and medical device development, offering unprecedented opportunities to accelerate innovation. We are particularly excited about the vast potential of in-silico trials and digital twins, which promise to reduce development costs, shorten the time to commercialization and minimize the risks to patients. For example, virtual clinical trials could be undertaken for rare diseases, where recruiting sufficient patient populations for traditional clinical trials can be challenging and impractical."
Read the Mergers & Acquisitions article for more.